Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pegylated liposomal doxorubicin plus daily oral cyclophosphamide in metastatic breast cancer
2007-003278-24Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Nov 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of doxorubicin and cyclophosphamide in breast cancer (2 arms), sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Time to progression difference. Started Nov 2007; status: terminated.
02
Drugs
doxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-003278-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003278-24.